Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies

Urological malignancies represent major challenges for clinicians, with annually rising incidences. In addition, cisplatin treatment induced long-term toxicities and the development of therapy resistance emphasize the need for novel therapeutics. In this study, we analyzed the effects of novel histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmeister, Aaron, Stephan, Alexa, Alves Avelar, Leandro A., Müller, Melanie R., Seiwert, Andrea, Höfmann, Stefan, Fischer, Fabian, Torres-Gomez, Hector, Hoffmann, Michèle J., Niegisch, Guenter, Bremmer, Felix, Petzsch, Patrick, Köhrer, Karl, Albers, Peter, Kurz, Thomas, Skowron, Margaretha A., Nettersheim, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630828/
https://www.ncbi.nlm.nih.gov/pubmed/35999659
http://dx.doi.org/10.1158/1535-7163.MCT-22-0207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630828/
https://www.ncbi.nlm.nih.gov/pubmed/35999659
http://dx.doi.org/10.1158/1535-7163.MCT-22-0207

Ejemplares similares